Published in Int J Antimicrob Agents on October 22, 2007
Knowledge, attitudes, and practices of parents in rural China on the use of antibiotics in children: a cross-sectional study. BMC Infect Dis (2014) 1.12
Antibiotic identification, use, and self-medication for respiratory illnesses among urban Latinos. J Am Acad Nurse Pract (2010) 0.90
Antibiotic use: a cross-sectional survey assessing the knowledge, attitudes and practices amongst students of a school of medicine in Italy. PLoS One (2015) 0.81
Antibiotic use in rural China: a cross-sectional survey of knowledge, attitudes and self-reported practices among caregivers in Shandong province. BMC Infect Dis (2015) 0.77
Inappropriate habits of antibiotic use among medical specialists and students in Vilnius. Acta Med Litu (2016) 0.75
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis (2013) 6.60
A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol (2012) 3.72
Generic and therapeutic substitutions in the UK: are they a good thing? Br J Clin Pharmacol (2010) 1.96
The problem of orphan drugs. BMJ (2010) 1.80
Clonal relatedness and conserved integron structures in epidemiologically unrelated Pseudomonas aeruginosa strains producing the VIM-1 metallo-{beta}-lactamase from different Italian hospitals. Antimicrob Agents Chemother (2005) 1.77
Parenting programme for parents of children at risk of developing conduct disorder: cost effectiveness analysis. BMJ (2007) 1.73
AcrAB Efflux System: Expression and Contribution to Fluoroquinolone Resistance in Klebsiella spp. Antimicrob Agents Chemother (2002) 1.51
The difference between effectiveness and efficacy of antimalarial drugs in Kenya. Trop Med Int Health (2004) 1.46
Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain. Health Econ (2012) 1.44
A European care bundle for prevention of ventilator-associated pneumonia. Intensive Care Med (2010) 1.40
Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis (2008) 1.37
Nurse-led vs. conventional physician-led follow-up for patients with cancer: systematic review. J Adv Nurs (2009) 1.36
Follow-up of cancer in primary care versus secondary care: systematic review. Br J Gen Pract (2009) 1.29
Patients' and healthcare professionals' views of cancer follow-up: systematic review. Br J Gen Pract (2009) 1.28
NICE and new: appraising innovation. BMJ (2010) 1.26
Azithromycin to prevent Pseudomonas aeruginosa ventilator-associated pneumonia by inhibition of quorum sensing: a randomized controlled trial. Intensive Care Med (2012) 1.22
Value-based pricing: incentive for innovation or zero net benefit? Pharmacoeconomics (2011) 1.19
Understanding medication compliance and persistence from an economics perspective. Value Health (2008) 1.14
Detection of Pseudomonas aeruginosa cell-to-cell signals in lung tissue of cystic fibrosis patients. Microb Pathog (2002) 1.11
Methods for the collection of resource use data within clinical trials: a systematic review of studies funded by the UK Health Technology Assessment program. Value Health (2010) 1.10
Detection of VIM-5 metallo-beta-lactamase in a Pseudomonas aeruginosa clinical isolate from Turkey. J Antimicrob Chemother (2004) 1.10
Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. Pharmacogenet Genomics (2009) 1.09
Defining rewardable innovation in drug therapy. Nat Rev Drug Discov (2012) 1.07
Isolation from blood culture of a Leclercia adecarboxylata strain producing an SHV-12 extended-spectrum beta-lactamase. J Clin Microbiol (2003) 1.06
Learning from mistakes: Taq polymerase contaminated with beta-lactamase sequences results in false emergence of Streptococcus pneumoniae containing TEM. J Antimicrob Chemother (2007) 1.06
Impact of interventions on medication adherence and blood pressure control in patients with essential hypertension: a systematic review by the ISPOR medication adherence and persistence special interest group. Value Health (2013) 1.05
Non-compliance with antibiotic therapy for acute community infections: a global survey. Int J Antimicrob Agents (2007) 1.03
Unusual resistance patterns in macrolide-resistant Streptococcus pyogenes harbouring erm(A). J Antimicrob Chemother (2008) 0.98
From NCE to NICE: the role of pharmacoeconomics. Br J Clin Pharmacol (2010) 0.98
Development of a database of instruments for resource-use measurement: purpose, feasibility, and design. Value Health (2012) 0.95
A European care bundle for management of ventilator-associated pneumonia. J Crit Care (2011) 0.93
Identification of a blaVIM-4 gene in the internationally successful Klebsiella pneumoniae ST11 clone and in a Klebsiella oxytoca strain in Hungary. J Antimicrob Chemother (2010) 0.92
Pharmacogenetic tests: the need for a level playing field. Nat Rev Drug Discov (2013) 0.92
Supranational surveillance of antimicrobial resistance: The legacy of the last decade and proposals for the future. Drug Resist Updat (2010) 0.87
Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae. J Antimicrob Chemother (2007) 0.86
Adherence and variability in warfarin dose requirements: assessment in a prospective cohort. Pharmacogenomics (2013) 0.85
NDM-1-producing Klebsiella pneumoniae, Croatia. Emerg Infect Dis (2012) 0.85
Mechanism-based approach to the economic evaluation of pharmaceuticals: pharmacokinetic/pharmacodynamic/pharmacoeconomic analysis of rituximab for follicular lymphoma. Pharmacoeconomics (2012) 0.85
Amino acid residues essential for function of the MexF efflux pump protein of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2002) 0.84
The importance of understanding the human-animal interface : from early hominins to global citizens. Curr Top Microbiol Immunol (2013) 0.83
A framework for planning and critiquing medication compliance and persistence research using prospective study designs. Clin Ther (2009) 0.82
Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy. Epilepsia (2015) 0.82
Decision-makers' preferences for approving new medicines in Wales: a discrete-choice experiment with assessment of external validity. Pharmacoeconomics (2013) 0.82
Warfarin pharmacogenetics: economic considerations. Pharmacoeconomics (2007) 0.81
Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. Pharmacogenomics (2012) 0.81
Professional challenges and opportunities in clinical microbiology and infectious diseases in Europe. Lancet Infect Dis (2011) 0.81
Telithromycin activity is reduced by efflux in Streptococcus pyogenes. J Antimicrob Chemother (2005) 0.80
Taxonomy for methods of resource use measurement. Health Econ (2014) 0.79
Reimbursement decisions of the All Wales Medicines Strategy Group: influence of policy and clinical and economic factors. Pharmacoeconomics (2012) 0.79
A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. Pharmacogenomics (2010) 0.79
Persistent macrolide resistance among group A streptococci: the lack of accomplishment after 4 decades. Clin Infect Dis (2005) 0.79
KPC-3 carbapenemase harbored in FIIk plasmid from Klebsiella pneumoniae ST512 and Escherichia coli ST43 in the same patient. Microb Drug Resist (2014) 0.77
Abolition of prescription charges in Wales: the impact on medicines use in those who used to pay. Int J Pharm Pract (2010) 0.77
First report of KPC-producing Klebsiella pneumoniae in Croatia. J Chemother (2012) 0.77
Current trends in the antibiotic therapy of uncomplicated Acute Otitis Media in children: concluding remarks. Clin Microbiol Infect (1997) 0.77
Identification of blaLAP-₂ and qnrS1 genes in the internationally successful Klebsiella pneumoniae ST147 clone. J Med Microbiol (2012) 0.76
Pilot implementation of the e-Bug Project in Italy. J Antimicrob Chemother (2011) 0.76
Viable Newcastle disease vaccine strains in a pharmaceutical dump. Emerg Infect Dis (2007) 0.75
Comment on: Redefining extended-spectrum beta-lactamases: balancing science and clinical need. J Antimicrob Chemother (2009) 0.75
Co-infection by two linezolid-resistant coagulase-negative staphylococci with two different resistance determinants. Scand J Infect Dis (2012) 0.75
Cisplatin plus vinorelbine or gemcitabine in patients with advanced non-small cell lung cancer: pharmacoeconomic considerations. Eur J Cancer (2005) 0.75
Hospital antibiotic management in north-eastern Italy--results of the ABS maturity survey of the ABS International group. Wien Klin Wochenschr (2008) 0.75
NHS and charitable funding for children and young people with cancer in England and Wales. J Child Health Care (2008) 0.75
Abolition of prescription copayments in Wales: an observational study on dispensing rates. Value Health (2010) 0.75
Rifampin-bonded vascular grafts and postoperative infections. Ann Vasc Surg (2011) 0.75